Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
One tolvaptan 15 mg tablet or placebo tablet will be orally administered once daily in the
morning for up to 14 days to heart failure patients with volume overload that does not show
adequate response to other diuretics such as loop diuretics in order to investigate the
effect of tolvaptan on the mid- to long-term prognosis of the target population. The efficacy
of tolvaptan during the treatment period will also be investigated.